|
CBX2 expression profile based on
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| ER negative-vs-ER positive | 2.55025846742632E-16
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| HER2 Negative-vs-HER2 Positive | 1.27426976825516E-05
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| PR Negative-vs-PR Positive | 1.59494376738332E-14
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
| Comparison | Statistical significance |
| Ki67 Low-vs-Ki67 High | 3.3226592740274E-17
|
|
Staaf J, Häkkinen J, Hegardt C, et al. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. NPJ Breast Cancer. 2022;8(1):94. Published 2022 Aug 16. doi:10.1038/s41523-022-00465-3
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Grade 1-vs-Grade 2 |
1.074414E-02 |
| Grade 1-vs-Grade 3 |
4.48509566090208E-26 |
| Grade 2-vs-Grade 3 |
3.27443433518003E-21 |
|
|